APO Research
Talk to an analyst

APO RESEARCH · REPORT

Self-replicating mRNA Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Self-replicating mRNA Vaccines Market Outlook and Growth Opportunities 2026

27 December 2025196 pages

Choose your research edition.

Industry ResearchSelf-replicating mRNA Vaccines Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Self-replicating mRNA Vaccines Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Self-replicating mRNA Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Self-replicating mRNA Vaccines Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Self-replicating mRNA Vaccines Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Self-replicating mRNA Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Self-replicating mRNA Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Self-replicating mRNA Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Self-replicating mRNA Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Self-replicating mRNA Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Self-replicating mRNA Vaccines market include Aldevron, Arcturus Therapeutics, BioNTech, Chimeron Bio, CSL, Elixirgen Therapeutics, Gritstone Bio, Precision Nanosystems and Replicate Bioscience, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Self-replicating mRNA Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Self-replicating mRNA Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Self-replicating mRNA Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Self-replicating mRNA Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Self-replicating mRNA Vaccines Segment by Company

Aldevron

Arcturus Therapeutics

BioNTech

Chimeron Bio

CSL

Elixirgen Therapeutics

Gritstone Bio

Precision Nanosystems

Replicate Bioscience

VaxEquity

Ziphius Vaccines

GSK

Immorna

Self-replicating mRNA Vaccines Segment by Type

Preventive Medicine

Medicine

Self-replicating mRNA Vaccines Segment by Application

Infectious Disease

Cancer

Others

Self-replicating mRNA Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Self-replicating mRNA Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Self-replicating mRNA Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Self-replicating mRNA Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze Self-replicating mRNA Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Self-replicating mRNA Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Self-replicating mRNA Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Self-replicating mRNA Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Self-replicating mRNA Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Self-replicating mRNA Vaccines industry.

Chapter 3: Detailed analysis of Self-replicating mRNA Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Self-replicating mRNA Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Self-replicating mRNA Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Self-replicating mRNA Vaccines Industry Trends Table 2. Self-replicating mRNA Vaccines Industry Drivers Table 3. Self-replicating mRNA Vaccines Industry Opportunities and Challenges Table 4. Self-replicating mRNA Vaccines Industry Restraints Table 5. Global Self-replicating mRNA Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Self-replicating mRNA Vaccines Revenue Share by Company (2021-2026) Table 7. Global Self-replicating mRNA Vaccines Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Self-replicating mRNA Vaccines Sales Volume Share by Company (2021-2026) Table 9. Global Self-replicating mRNA Vaccines Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Self-replicating mRNA Vaccines Company Ranking, (2024-2026) & (USD Million) Table 11. Global Self-replicating mRNA Vaccines Key Company Manufacturing Base & Headquarters Table 12. Global Self-replicating mRNA Vaccines Company, Product Type & Application Table 13. Global Self-replicating mRNA Vaccines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Self-replicating mRNA Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Preventive Medicine Table 18. Significant Companies of Medicine Table 19. Global Self-replicating mRNA Vaccines Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Self-replicating mRNA Vaccines Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Self-replicating mRNA Vaccines Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Self-replicating mRNA Vaccines Sales Volume Share by Type (2021-2026) Table 23. Global Self-replicating mRNA Vaccines Sales Volume Share by Type (2027-2032) Table 24. Global Self-replicating mRNA Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Self-replicating mRNA Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Self-replicating mRNA Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Self-replicating mRNA Vaccines Sales Value Share by Type (2021-2026) Table 28. Global Self-replicating mRNA Vaccines Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Infectious Disease Table 30. Significant Companies of Cancer Table 31. Significant Companies of Others Table 32. Global Self-replicating mRNA Vaccines Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Self-replicating mRNA Vaccines Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Self-replicating mRNA Vaccines Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Self-replicating mRNA Vaccines Sales Volume Share by Application (2021-2026) Table 36. Global Self-replicating mRNA Vaccines Sales Volume Share by Application (2027-2032) Table 37. Global Self-replicating mRNA Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Self-replicating mRNA Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Self-replicating mRNA Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Self-replicating mRNA Vaccines Sales Value Share by Application (2021-2026) Table 41. Global Self-replicating mRNA Vaccines Sales Value Share by Application (2027-2032) Table 42. Global Self-replicating mRNA Vaccines Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Self-replicating mRNA Vaccines Sales by Region (2021-2026) & (K Units) Table 44. Global Self-replicating mRNA Vaccines Sales Market Share by Region (2021-2026) Table 45. Global Self-replicating mRNA Vaccines Sales by Region (2027-2032) & (K Units) Table 46. Global Self-replicating mRNA Vaccines Sales Market Share by Region (2027-2032) Table 47. Global Self-replicating mRNA Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Self-replicating mRNA Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Self-replicating mRNA Vaccines Sales Value Share by Region (2021-2026) Table 50. Global Self-replicating mRNA Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Self-replicating mRNA Vaccines Sales Value Share by Region (2027-2032) Table 52. Global Self-replicating mRNA Vaccines Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Self-replicating mRNA Vaccines Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Self-replicating mRNA Vaccines Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Self-replicating mRNA Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Self-replicating mRNA Vaccines Sales by Country (2021-2026) & (K Units) Table 57. Global Self-replicating mRNA Vaccines Sales Market Share by Country (2021-2026) Table 58. Global Self-replicating mRNA Vaccines Sales by Country (2027-2032) & (K Units) Table 59. Global Self-replicating mRNA Vaccines Sales Market Share by Country (2027-2032) Table 60. Global Self-replicating mRNA Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Self-replicating mRNA Vaccines Sales Value Market Share by Country (2021-2026) Table 62. Global Self-replicating mRNA Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Self-replicating mRNA Vaccines Sales Value Market Share by Country (2027-2032) Table 64. Aldevron Company Information Table 65. Aldevron Business Overview Table 66. Aldevron Self-replicating mRNA Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Aldevron Self-replicating mRNA Vaccines Product Portfolio Table 68. Aldevron Recent Development Table 69. Arcturus Therapeutics Company Information Table 70. Arcturus Therapeutics Business Overview Table 71. Arcturus Therapeutics Self-replicating mRNA Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Arcturus Therapeutics Self-replicating mRNA Vaccines Product Portfolio Table 73. Arcturus Therapeutics Recent Development Table 74. BioNTech Company Information Table 75. BioNTech Business Overview Table 76. BioNTech Self-replicating mRNA Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. BioNTech Self-replicating mRNA Vaccines Product Portfolio Table 78. BioNTech Recent Development Table 79. Chimeron Bio Company Information Table 80. Chimeron Bio Business Overview Table 81. Chimeron Bio Self-replicating mRNA Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Chimeron Bio Self-replicating mRNA Vaccines Product Portfolio Table 83. Chimeron Bio Recent Development Table 84. CSL Company Information Table 85. CSL Business Overview Table 86. CSL Self-replicating mRNA Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. CSL Self-replicating mRNA Vaccines Product Portfolio Table 88. CSL Recent Development Table 89. Elixirgen Therapeutics Company Information Table 90. Elixirgen Therapeutics Business Overview Table 91. Elixirgen Therapeutics Self-replicating mRNA Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Elixirgen Therapeutics Self-replicating mRNA Vaccines Product Portfolio Table 93. Elixirgen Therapeutics Recent Development Table 94. Gritstone Bio Company Information Table 95. Gritstone Bio Business Overview Table 96. Gritstone Bio Self-replicating mRNA Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Gritstone Bio Self-replicating mRNA Vaccines Product Portfolio Table 98. Gritstone Bio Recent Development Table 99. Precision Nanosystems Company Information Table 100. Precision Nanosystems Business Overview Table 101. Precision Nanosystems Self-replicating mRNA Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Precision Nanosystems Self-replicating mRNA Vaccines Product Portfolio Table 103. Precision Nanosystems Recent Development Table 104. Replicate Bioscience Company Information Table 105. Replicate Bioscience Business Overview Table 106. Replicate Bioscience Self-replicating mRNA Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Replicate Bioscience Self-replicating mRNA Vaccines Product Portfolio Table 108. Replicate Bioscience Recent Development Table 109. VaxEquity Company Information Table 110. VaxEquity Business Overview Table 111. VaxEquity Self-replicating mRNA Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. VaxEquity Self-replicating mRNA Vaccines Product Portfolio Table 113. VaxEquity Recent Development Table 114. Ziphius Vaccines Company Information Table 115. Ziphius Vaccines Business Overview Table 116. Ziphius Vaccines Self-replicating mRNA Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Ziphius Vaccines Self-replicating mRNA Vaccines Product Portfolio Table 118. Ziphius Vaccines Recent Development Table 119. GSK Company Information Table 120. GSK Business Overview Table 121. GSK Self-replicating mRNA Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. GSK Self-replicating mRNA Vaccines Product Portfolio Table 123. GSK Recent Development Table 124. Immorna Company Information Table 125. Immorna Business Overview Table 126. Immorna Self-replicating mRNA Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Immorna Self-replicating mRNA Vaccines Product Portfolio Table 128. Immorna Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Self-replicating mRNA Vaccines Distributors List Table 132. Self-replicating mRNA Vaccines Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Self-replicating mRNA Vaccines Product Image Figure 2. Global Self-replicating mRNA Vaccines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Self-replicating mRNA Vaccines Sales Value (2021-2032) & (US$ Million) Figure 4. Global Self-replicating mRNA Vaccines Sales (2021-2032) & (K Units) Figure 5. Global Self-replicating mRNA Vaccines Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Self-replicating mRNA Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Preventive Medicine Image Figure 10. Medicine Image Figure 11. Global Self-replicating mRNA Vaccines Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Self-replicating mRNA Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Self-replicating mRNA Vaccines Sales Volume Share by Type (2021-2032) Figure 14. Global Self-replicating mRNA Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Self-replicating mRNA Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Self-replicating mRNA Vaccines Sales Value Share by Type (2021-2032) Figure 17. Infectious Disease Image Figure 18. Cancer Image Figure 19. Others Image Figure 20. Global Self-replicating mRNA Vaccines Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Self-replicating mRNA Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Self-replicating mRNA Vaccines Sales Volume Share by Application (2021-2032) Figure 23. Global Self-replicating mRNA Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Self-replicating mRNA Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Self-replicating mRNA Vaccines Sales Value Share by Application (2021-2032) Figure 26. Global Self-replicating mRNA Vaccines Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Self-replicating mRNA Vaccines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Self-replicating mRNA Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Self-replicating mRNA Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Self-replicating mRNA Vaccines Sales Value (2021-2032) & (US$ Million) Figure 31. North America Self-replicating mRNA Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Self-replicating mRNA Vaccines Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Self-replicating mRNA Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Self-replicating mRNA Vaccines Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Self-replicating mRNA Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Self-replicating mRNA Vaccines Sales Value (2021-2032) & (US$ Million) Figure 37. South America Self-replicating mRNA Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Self-replicating mRNA Vaccines Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Self-replicating mRNA Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Self-replicating mRNA Vaccines Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Self-replicating mRNA Vaccines Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Preventive Medicine
  • Medicine
Applications
  • Infectious Disease
  • Cancer
  • Others
Companies covered
  • Aldevron
  • Arcturus Therapeutics
  • BioNTech
  • Chimeron Bio
  • CSL
  • Elixirgen Therapeutics
  • Gritstone Bio
  • Precision Nanosystems
  • Replicate Bioscience
  • VaxEquity
  • Ziphius Vaccines
  • GSK
  • Immorna

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Self-replicating mRNA Vaccines Sales Value (2021-2032)
  4. 1.2.2 Global Self-replicating mRNA Vaccines Sales Volume (2021-2032)
  5. 1.2.3 Global Self-replicating mRNA Vaccines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Self-replicating mRNA Vaccines Market Dynamics
  1. 2.1 Self-replicating mRNA Vaccines Industry Trends
  2. 2.2 Self-replicating mRNA Vaccines Industry Drivers
  3. 2.3 Self-replicating mRNA Vaccines Industry Opportunities and Challenges
  4. 2.4 Self-replicating mRNA Vaccines Industry Restraints
3 Self-replicating mRNA Vaccines Market by Company
  1. 3.1 Global Self-replicating mRNA Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global Self-replicating mRNA Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global Self-replicating mRNA Vaccines Sales Volume by Company (2021-2026)
  4. 3.4 Global Self-replicating mRNA Vaccines Average Price by Company (2021-2026)
  5. 3.5 Global Self-replicating mRNA Vaccines Company Ranking (2024-2026)
  6. 3.6 Global Self-replicating mRNA Vaccines Company Manufacturing Base and Headquarters
  7. 3.7 Global Self-replicating mRNA Vaccines Company Product Type and Application
  8. 3.8 Global Self-replicating mRNA Vaccines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Self-replicating mRNA Vaccines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Self-replicating mRNA Vaccines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Self-replicating mRNA Vaccines Market by Type
  1. 4.1 Self-replicating mRNA Vaccines Type Introduction
  2. 4.1.1 Preventive Medicine
  3. 4.1.2 Medicine
  4. 4.2 Global Self-replicating mRNA Vaccines Sales Volume by Type
  5. 4.2.1 Global Self-replicating mRNA Vaccines Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Self-replicating mRNA Vaccines Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Self-replicating mRNA Vaccines Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Self-replicating mRNA Vaccines Sales Value by Type
  9. 4.3.1 Global Self-replicating mRNA Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Self-replicating mRNA Vaccines Sales Value by Type (2021-2032)
  11. 4.3.3 Global Self-replicating mRNA Vaccines Sales Value Share by Type (2021-2032)
5 Self-replicating mRNA Vaccines Market by Application
  1. 5.1 Self-replicating mRNA Vaccines Application Introduction
  2. 5.1.1 Infectious Disease
  3. 5.1.2 Cancer
  4. 5.1.3 Others
  5. 5.2 Global Self-replicating mRNA Vaccines Sales Volume by Application
  6. 5.2.1 Global Self-replicating mRNA Vaccines Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Self-replicating mRNA Vaccines Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Self-replicating mRNA Vaccines Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Self-replicating mRNA Vaccines Sales Value by Application
  10. 5.3.1 Global Self-replicating mRNA Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Self-replicating mRNA Vaccines Sales Value by Application (2021-2032)
  12. 5.3.3 Global Self-replicating mRNA Vaccines Sales Value Share by Application (2021-2032)
6 Self-replicating mRNA Vaccines Regional Sales and Value Analysis
  1. 6.1 Global Self-replicating mRNA Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Self-replicating mRNA Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Self-replicating mRNA Vaccines Sales by Region: 2021-2026
  4. 6.2.2 Global Self-replicating mRNA Vaccines Sales by Region (2027-2032)
  5. 6.3 Global Self-replicating mRNA Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Self-replicating mRNA Vaccines Sales Value by Region (2021-2032)
  7. 6.4.1 Global Self-replicating mRNA Vaccines Sales Value by Region: 2021-2026
  8. 6.4.2 Global Self-replicating mRNA Vaccines Sales Value by Region (2027-2032)
  9. 6.5 Global Self-replicating mRNA Vaccines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Self-replicating mRNA Vaccines Sales Value (2021-2032)
  12. 6.6.2 North America Self-replicating mRNA Vaccines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Self-replicating mRNA Vaccines Sales Value (2021-2032)
  15. 6.7.2 Europe Self-replicating mRNA Vaccines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Self-replicating mRNA Vaccines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Self-replicating mRNA Vaccines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Self-replicating mRNA Vaccines Sales Value (2021-2032)
  21. 6.9.2 South America Self-replicating mRNA Vaccines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Self-replicating mRNA Vaccines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Self-replicating mRNA Vaccines Sales Value Share by Country, 2025 VS 2032
7 Self-replicating mRNA Vaccines Country-level Sales and Value Analysis
  1. 7.1 Global Self-replicating mRNA Vaccines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Self-replicating mRNA Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Self-replicating mRNA Vaccines Sales by Country (2021-2032)
  4. 7.3.1 Global Self-replicating mRNA Vaccines Sales by Country (2021-2026)
  5. 7.3.2 Global Self-replicating mRNA Vaccines Sales by Country (2027-2032)
  6. 7.4 Global Self-replicating mRNA Vaccines Sales Value by Country (2021-2032)
  7. 7.4.1 Global Self-replicating mRNA Vaccines Sales Value by Country (2021-2026)
  8. 7.4.2 Global Self-replicating mRNA Vaccines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Self-replicating mRNA Vaccines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Self-replicating mRNA Vaccines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Self-replicating mRNA Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Aldevron
  2. 8.1.1 Aldevron Company Information
  3. 8.1.2 Aldevron Business Overview
  4. 8.1.3 Aldevron Self-replicating mRNA Vaccines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Aldevron Self-replicating mRNA Vaccines Product Portfolio
  6. 8.1.5 Aldevron Recent Developments
  7. 8.2 Arcturus Therapeutics
  8. 8.2.1 Arcturus Therapeutics Company Information
  9. 8.2.2 Arcturus Therapeutics Business Overview
  10. 8.2.3 Arcturus Therapeutics Self-replicating mRNA Vaccines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Arcturus Therapeutics Self-replicating mRNA Vaccines Product Portfolio
  12. 8.2.5 Arcturus Therapeutics Recent Developments
  13. 8.3 BioNTech
  14. 8.3.1 BioNTech Company Information
  15. 8.3.2 BioNTech Business Overview
  16. 8.3.3 BioNTech Self-replicating mRNA Vaccines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 BioNTech Self-replicating mRNA Vaccines Product Portfolio
  18. 8.3.5 BioNTech Recent Developments
  19. 8.4 Chimeron Bio
  20. 8.4.1 Chimeron Bio Company Information
  21. 8.4.2 Chimeron Bio Business Overview
  22. 8.4.3 Chimeron Bio Self-replicating mRNA Vaccines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Chimeron Bio Self-replicating mRNA Vaccines Product Portfolio
  24. 8.4.5 Chimeron Bio Recent Developments
  25. 8.5 CSL
  26. 8.5.1 CSL Company Information
  27. 8.5.2 CSL Business Overview
  28. 8.5.3 CSL Self-replicating mRNA Vaccines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 CSL Self-replicating mRNA Vaccines Product Portfolio
  30. 8.5.5 CSL Recent Developments
  31. 8.6 Elixirgen Therapeutics
  32. 8.6.1 Elixirgen Therapeutics Company Information
  33. 8.6.2 Elixirgen Therapeutics Business Overview
  34. 8.6.3 Elixirgen Therapeutics Self-replicating mRNA Vaccines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Elixirgen Therapeutics Self-replicating mRNA Vaccines Product Portfolio
  36. 8.6.5 Elixirgen Therapeutics Recent Developments
  37. 8.7 Gritstone Bio
  38. 8.7.1 Gritstone Bio Company Information
  39. 8.7.2 Gritstone Bio Business Overview
  40. 8.7.3 Gritstone Bio Self-replicating mRNA Vaccines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Gritstone Bio Self-replicating mRNA Vaccines Product Portfolio
  42. 8.7.5 Gritstone Bio Recent Developments
  43. 8.8 Precision Nanosystems
  44. 8.8.1 Precision Nanosystems Company Information
  45. 8.8.2 Precision Nanosystems Business Overview
  46. 8.8.3 Precision Nanosystems Self-replicating mRNA Vaccines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Precision Nanosystems Self-replicating mRNA Vaccines Product Portfolio
  48. 8.8.5 Precision Nanosystems Recent Developments
  49. 8.9 Replicate Bioscience
  50. 8.9.1 Replicate Bioscience Company Information
  51. 8.9.2 Replicate Bioscience Business Overview
  52. 8.9.3 Replicate Bioscience Self-replicating mRNA Vaccines Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Replicate Bioscience Self-replicating mRNA Vaccines Product Portfolio
  54. 8.9.5 Replicate Bioscience Recent Developments
  55. 8.10 VaxEquity
  56. 8.10.1 VaxEquity Company Information
  57. 8.10.2 VaxEquity Business Overview
  58. 8.10.3 VaxEquity Self-replicating mRNA Vaccines Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 VaxEquity Self-replicating mRNA Vaccines Product Portfolio
  60. 8.10.5 VaxEquity Recent Developments
  61. 8.11 Ziphius Vaccines
  62. 8.11.1 Ziphius Vaccines Company Information
  63. 8.11.2 Ziphius Vaccines Business Overview
  64. 8.11.3 Ziphius Vaccines Self-replicating mRNA Vaccines Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Ziphius Vaccines Self-replicating mRNA Vaccines Product Portfolio
  66. 8.11.5 Ziphius Vaccines Recent Developments
  67. 8.12 GSK
  68. 8.12.1 GSK Company Information
  69. 8.12.2 GSK Business Overview
  70. 8.12.3 GSK Self-replicating mRNA Vaccines Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 GSK Self-replicating mRNA Vaccines Product Portfolio
  72. 8.12.5 GSK Recent Developments
  73. 8.13 Immorna
  74. 8.13.1 Immorna Company Information
  75. 8.13.2 Immorna Business Overview
  76. 8.13.3 Immorna Self-replicating mRNA Vaccines Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Immorna Self-replicating mRNA Vaccines Product Portfolio
  78. 8.13.5 Immorna Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Self-replicating mRNA Vaccines Value Chain Analysis
  2. 9.1.1 Self-replicating mRNA Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Self-replicating mRNA Vaccines Sales Mode & Process
  6. 9.2 Self-replicating mRNA Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Self-replicating mRNA Vaccines Distributors
  9. 9.2.3 Self-replicating mRNA Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst